Pharmacometric evaluation of pre‐referral rectal artesunate in children with severe malaria
British Journal of Clinical Pharmacology · 29.07.2026
DOI: 10.1002/bcp.70723 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 29.07.2026. Verfasst von Ayorinde Adehin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust-Mahidol University-Oxford Tropical Medicine Research Programme, Li Ka Shing Foundation, Gates Foundation.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Aims
Parenteral artesunate is the preferred first‐line treatment for severe malaria. Pre‐referral rectal artesunate suppositories are recommended where parenteral treatment is inaccessible. In this study, we compared dihydroartemisinin exposure and model‐predicted early parasite clearance following rectal artesunate and intravenous artesunate in African children with severe malaria.
Methods
A total of 82 African children with severe malaria participated in a randomized crossover study in Democratic Republic of Congo. Forty children received rectal artesunate (10 mg/kg) while the other 42 received intravenous artesunate (2.4 mg/kg) as the first intervention, and then the other route of administration for the second dose. Blood samples were drawn for drug quantification, and nonlinear mixed‐effects modelling was used to evaluate the pharmacokinetic properties of intravenous and rectal artesunate and to simulate expected parasite clearance associated with these routes of administration.
Results
The mean individually estimated rectal bioavailability of artesunate was 21% but was highly variable (IQR: 8%–35%). Plasma exposure to dihydroartemisinin—the principal and bioactive metabolite of artesunate—did not differ significantly between rectal and intravenous administration. Predicted parasite reduction over the first 12 h was similar for both routes, consistent with previously reported clinical benefits of rectal artesunate.
Conclusions
These findings support the 10‐mg/kg dose of rectal artesunate as a pre‐referral intervention, which should be more widely deployed in malaria‐endemic areas.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
- Kinshasa School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
ORCID-Profile: Ayorinde Adehin, Marie A Onyamboko, Caterina Fanello, Nicholas J White, Nicholas P J Day, Richard M Hoglund, Joel Tarning
Förderung
- Wellcome Trust-Mahidol University-Oxford Tropical Medicine Research Programme
- Li Ka Shing Foundation
- Gates Foundation
- Wellcome Trust
- Bill and Melinda Gates Foundation
Zitieren
APA
Adehin, A., Onyamboko, M. A., Fanello, C., White, N. J., Day, N. P. J., Hoglund, R. M., & Tarning, J. (2026). Pharmacometric evaluation of pre‐referral rectal artesunate in children with severe malaria. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70723
Vancouver
Adehin A, Onyamboko MA, Fanello C, White NJ, Day NPJ, Hoglund RM, et al. Pharmacometric evaluation of pre‐referral rectal artesunate in children with severe malaria. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70723
BibTeX
@article{Adehin2026,
author = {Adehin, Ayorinde and Onyamboko, Marie A and Fanello, Caterina and White, Nicholas J and Day, Nicholas P J and Hoglund, Richard M and Tarning, Joel},
title = {Pharmacometric evaluation of pre‐referral rectal artesunate in children with severe malaria},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70723}
}
EUVIMED